Journal article · 2025 · Open access
Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation
JAMA, 334(24), 2186 · Published 24 November 2025 · DOI 10.1001/jama.2025.20951
In brief
“Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation” is a 2025 journal article by Jacqueline Maya and 11 co-authors, published in JAMA. OpenAlex counts 84 citations as of 17 November 2026. It is open access: the full text is free to read at PubMed Central.
- Citations
- 84
- Most cited in
- 2026 (83)
- Field-weighted impact
- 56.91
- References
- 37
- Authors
- 12
Abstract
Importance: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are contraindicated in pregnancy. Discontinuation of GLP-1RAs proximal to pregnancy could affect gestational weight gain and pregnancy outcomes. Objective: To compare gestational weight gain and pregnancy outcomes with and without exposure to GLP-1RAs before or during early pregnancy. Design, Setting, and Participants: Retrospective cohort study of 149 790 singleton pregnancies delivered between June 1, 2016, and March 31, 2025, within a single academic health system. Exposure: A GLP-1RA order between 3 years before and 90 days after conception, with propensity score matching of each exposed pregnancy to 3 unexposed pregnancies. Main Outcomes and Measures: The primary outcome was gestational weight gain. Secondary outcomes were excess gestational weight gain, large and small for gestational age birth weight, birth weight percentile for gestational age and sex, birth length, preterm delivery, cesarean delivery, gestational diabetes, and hypertensive disorders of pregnancy. Results: Among 149 790 pregnancies during the study period, 1792 (448 exposed and 1344 unexposed) were matched for the primary analysis. Exposed pregnancies had mean maternal age of 34.0 years (SD, 4.7 years) and prepregnancy body mass index of 36.1 (SD, 6.5; calculated as weight in kilograms divided by height in meters squared); 378 of 448 (84%) had obesity and 104 of 448 (23%) had preexisting diabetes; 136 (30%) were Hispanic, 49 (11%) were non-Hispanic Black, and 223 (50%) were non-Hispanic White; and 43 (10%) had public insurance. The GLP-1RA-exposed pregnancies had greater gestational weight gain (mean, 13.7 kg [SD, 9.2]) than propensity score-matched unexposed pregnancies (mean, 10.5 kg [SD, 8.0]), a difference of 3.3 kg (95% CI, 2.3-4.2; P < .001). The GLP-1RA-exposed group had a higher risk of excess gestational weight gain (65% vs 49%; risk ratio [RR], 1.32; 95% CI, 1.19-1.47), greater mean birth weight percentile (58.4% vs 54.8%; difference, 3.6%; 95% CI, 0.2%-6.9%), and higher risk of preterm delivery (17% vs 13%; RR, 1.34; 95% CI, 1.06-1.69), gestational diabetes (20% vs 15%; RR, 1.30; 95% CI, 1.01-1.68), and hypertensive disorders of pregnancy (46% vs 36%; RR, 1.29; 95% CI, 1.12-1.49). There was no difference in birth length, risk of large or small for gestational age birth weight, or cesarean delivery. Conclusions and Relevance: In a cohort composed primarily of women with obesity, GLP-1RA use with subsequent prepregnancy or early pregnancy discontinuation was associated with more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Maya, J., Pant, D. B., Fu, Y., James, K. E., Camero, C. B., Hsu, S. C., Soria‐Contreras, D. C., Shook, L. L., Mow, C., Hivert, M., Thaweethai, T., & Powe, C. E. (2025). Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. JAMA, 334(24), 2186. https://doi.org/10.1001/jama.2025.20951
MLA 9
Maya, Jacqueline, et al. “Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation.” JAMA, vol. 334, no. 24, 2025, p. 2186. https://doi.org/10.1001/jama.2025.20951.
Chicago
Maya, Jacqueline, Deepti B. Pant, Yiran Fu, Kaitlyn E. James, Carolina Batlle Camero, Sarah C Hsu, Diana C. Soria‐Contreras, et al. 2025. “Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation.” JAMA 334 (24): 2186. https://doi.org/10.1001/jama.2025.20951.
Harvard
Maya, J. et al. (2025) ‘Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation’, JAMA, 334(24), p. 2186. doi:10.1001/jama.2025.20951.
IEEE
J. Maya et al., “Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation,” JAMA, vol. 334, no. 24, p. 2186, 2025, doi: 10.1001/jama.2025.20951.
BibTeX
@article{maya2025gestational,
title = {{Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation}},
author = {Maya, Jacqueline and Pant, Deepti B. and Fu, Yiran and James, Kaitlyn E. and Camero, Carolina Batlle and Hsu, Sarah C and Soria‐Contreras, Diana C. and Shook, Lydia L. and Mow, Christopher and Hivert, Marie‐France and Thaweethai, Tanayott and Powe, Camille Elise},
journal = {JAMA},
year = {2025},
volume = {334},
number = {24},
pages = {2186},
doi = {10.1001/jama.2025.20951},
url = {https://doi.org/10.1001/jama.2025.20951}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- gestational weight gain
- GLP-1 receptor agonists
- pregnancy outcomes
- drug discontinuation
- excessive weight gain
- birth weight
- preterm birth
- cesarean section
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Maya, J., Pant, D. B., Fu, Y., James, K. E., Camero, C. B., Hsu, S. C., Soria‐Contreras, D. C., Shook, L. L., Mow, C., Hivert, M., Thaweethai, T., & Powe, C. E. (2025). Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. JAMA, 334(24), 2186. https://doi.org/10.1001/jama.2025.20951
How many times has this paper been cited?
84 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Jacqueline Maya, Deepti B. Pant, Yiran Fu, Kaitlyn E. James, Carolina Batlle Camero, Sarah C Hsu, Diana C. Soria‐Contreras, Lydia L. Shook, Christopher Mow, Marie‐France Hivert, Tanayott Thaweethai, Camille Elise Powe.
What is the DOI of this paper?
10.1001/jama.2025.20951, permanently at https://doi.org/10.1001/jama.2025.20951. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.